이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Immatics 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Harpreet Singh

최고 경영자

€6.4m

총 보상

CEO 급여 비율	7.7%
CEO 임기	5yrs
CEO 소유권	1.2%
경영진 평균 재임 기간	4.1yrs
이사회 평균 재임 기간	3.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Harpreet Singh 의 보수는 Immatics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-€80m
Dec 31 2023	€6m	€488k	-€97m
Sep 30 2023	n/a	n/a	-€84m
Jun 30 2023	n/a	n/a	-€79m
Mar 31 2023	n/a	n/a	-€68m
Dec 31 2022	€7m	€522k	€38m

보상 대 시장: Harpreet 의 총 보상 ($USD 6.85M )은 German 시장( $USD 1.53M ).

보상과 수익: Harpreet 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Harpreet Singh (49 yo)

5yrs

테뉴어

€6,378,000

보상

Dr. Harpreet Singh, Ph D., has been Non-Executive Director of Immatics N.V. since July 1, 2021 and served as its Supervisory Director since 2021 until July 1, 2021. Dr. Singh serves as Chief Executive Offi...

리더십 팀

이름	위치	테뉴어	보상	소유권
Harpreet Singh	CEO, MD	5yrs	€6.38m	1.24% € 13.8m
Toni Weinschenk	Co-Founder & Chief Innovation Officer	24.5yrs	데이터 없음	0.31% € 3.5m
Arnd Christ	Chief Financial Officer	3.8yrs	데이터 없음	0.16% € 1.8m
Steffen Walter	Chief Operations Officer	1.3yrs	데이터 없음	0.27% € 3.0m
Edward Sturchio	General Counsel & Secretary	4yrs	데이터 없음	0.10% € 1.2m
Carsten Reinhardt	Chief Development Officer	4.8yrs	데이터 없음	0.45% € 5.0m
Cedrik Britten	Chief Medical Officer	4.1yrs	데이터 없음	0.22% € 2.5m
Jordan Silverstein	Head of Strategy	no data	데이터 없음	0.19% € 2.1m
Hans-Georg Rammensee	Co-Founder & Member of the Scientific Advisory Board	24.5yrs	데이터 없음	데이터 없음
Ephraim Hofsäß	Vice President of SEC Reporting & Accounting	less than a year	데이터 없음	데이터 없음
Emmanuelle Schuler	VP of Administration & Operations and US Site Head	no data	데이터 없음	데이터 없음
Rainer Kramer	Chief Business Officer & Site Head Munich	no data	데이터 없음	0.31% € 3.5m

4.1yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 관리: 4A3 의 관리팀은 경험 ( 4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Harpreet Singh	CEO, MD	3yrs	€6.38m	1.24% € 13.8m
Hans-Georg Rammensee	Co-Founder & Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Michael Atieh	Independent Non-Executive Director	3yrs	€263.00k	0.054% € 598.6k
Peter Chambré	Non-Executive Chairman	3yrs	€283.00k	0.36% € 4.0m
Heather Mason	Independent Vice Chair of the Board of Directors	3yrs	€246.00k	0.054% € 598.6k
Hidde L. Ploegh	Member of Scientific Advisory Board	4.1yrs	데이터 없음	데이터 없음
Patrick Hwu	Co-Chair of the Scientific Advisory Board	3.3yrs	데이터 없음	데이터 없음
Paul Rutherford Carter	Independent Non-Executive Director	3yrs	€259.00k	0.054% € 598.6k
Cassian Yee	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Gwendolyn Binder	Member of Scientific Advisory Board	4.5yrs	데이터 없음	데이터 없음
Crystal Mackall	Co-Chair of the Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음
Roland Kontermann	Member of Scientific Advisory Board	4yrs	데이터 없음	데이터 없음

3.2yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: 4A3 의 이사회는 경험(평균 재직 기간 3.1 년)으로 간주됩니다.

Immatics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Immatics N.V., Annual General Meeting, Jun 19, 2024

Immatics N.V., Annual General Meeting, Jun 20, 2023

Immatics N.V., Annual General Meeting, Jun 13, 2022

Recent updates

New major risk - Share price stability

First quarter 2024 earnings released: €0.03 loss per share (vs €0.26 loss in 1Q 2023)

New major risk - Financial position

New major risk - Revenue and earnings growth

Full year 2023 earnings released: €1.20 loss per share (vs €0.56 profit in FY 2022)

Immatics N.V., Annual General Meeting, Jun 19, 2024

Immatics N.V. has completed a Follow-on Equity Offering in the amount of $175.175 million.

Immatics N.V. has filed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

New major risk - Financial position

Immatics N.V. Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRame in an Ongoing Phase 1 Trial

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Immatics N.V. Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine(R) IMA203 TCR-T Monotherapy

New major risk - Share price stability

Immatics N.V. Initiates Phase 1/2 Clinical Trial to Evaluate Promame TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

Immatics N.V., Annual General Meeting, Jun 20, 2023

First quarter 2023 earnings released: €0.26 loss per share (vs €1.36 profit in 1Q 2022)

Investor sentiment improves as stock rises 49%

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: €0.56 (vs €1.48 loss in FY 2021)

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: €0.32 loss per share (vs €0.43 loss in 3Q 2021)

Immatics Reports Interim Clinical Data Update on Actengine(R) Ima203 Tcr-T Monotherapy Targeting Prame

Investor sentiment deteriorated over the past week

Immatics N.V. Presents Comprehensive Preclinical Data Set for Tcr Bispecific Candidate Ima402 Targeting Prame At European Society for Medical Oncology (Esmo) Congress 2022

Immatics N.V. Announces First Cancer Patient Treated with Second-Generation Actengine(R) Tcr-T Candidate Ima203cd8 Targeting Prame

Second quarter 2022 earnings released: €0.21 loss per share (vs €0.42 loss in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: €1.36 (vs €0.36 loss in 1Q 2021)

Immatics N.V., Annual General Meeting, Jun 13, 2022

Immatics N.V. Announces First Patient Treated with Actengine® Ima203 Tcr-T in Combination with Checkpoint Inhibitor Opdivo® (Nivolumab) in Patients with Advanced Solid Tumors

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Third quarter 2021 earnings released: €0.43 loss per share (vs €2.61 loss in 3Q 2020)

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령